Abeona Therapeutics (ABEO) Competitors $5.77 -0.12 (-2.04%) As of 03:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. VRDN, BGM, MNKD, NAGE, LQDA, PCRX, ABCL, WVE, NVAX, and NTLAShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Viridian Therapeutics (VRDN), BGM Group (BGM), MannKind (MNKD), Niagen Bioscience (NAGE), Liquidia Technologies (LQDA), Pacira BioSciences (PCRX), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Novavax (NVAX), and Intellia Therapeutics (NTLA). These companies are all part of the "med - biomed/gene" industry. Abeona Therapeutics vs. Its Competitors Viridian Therapeutics BGM Group MannKind Niagen Bioscience Liquidia Technologies Pacira BioSciences AbCellera Biologics WAVE Life Sciences Novavax Intellia Therapeutics Viridian Therapeutics (NASDAQ:VRDN) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Does the media prefer VRDN or ABEO? In the previous week, Abeona Therapeutics had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for Abeona Therapeutics and 2 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.87 beat Abeona Therapeutics' score of 0.26 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate VRDN or ABEO? Viridian Therapeutics presently has a consensus price target of $37.56, suggesting a potential upside of 136.35%. Abeona Therapeutics has a consensus price target of $19.25, suggesting a potential upside of 233.62%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Viridian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viridian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, VRDN or ABEO? Abeona Therapeutics has higher revenue and earnings than Viridian Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViridian Therapeutics$302K4,293.04-$269.95M-$3.85-4.13Abeona Therapeutics$3.50M84.34-$63.73M-$1.27-4.54 Which has more risk and volatility, VRDN or ABEO? Viridian Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Do insiders and institutionals have more ownership in VRDN or ABEO? 80.6% of Abeona Therapeutics shares are held by institutional investors. 1.6% of Viridian Therapeutics shares are held by insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is VRDN or ABEO more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -102,092.39%. Viridian Therapeutics' return on equity of -70.61% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viridian Therapeutics-102,092.39% -70.61% -44.67% Abeona Therapeutics N/A -118.82%-52.48% SummaryAbeona Therapeutics beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$295.19M$2.85B$5.45B$8.92BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-4.5420.6327.2720.07Price / Sales84.34290.56428.46118.22Price / CashN/A41.7026.2128.59Price / Book5.717.427.925.58Net Income-$63.73M-$55.04M$3.17B$248.65M7 Day Performance1.58%3.70%4.33%7.15%1 Month Performance-14.39%0.35%2.61%8.13%1 Year Performance27.09%4.79%34.78%21.59% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics4.0023 of 5 stars$5.77-2.0%$19.25+233.6%+30.0%$295.19M$3.50M-4.5490VRDNViridian Therapeutics1.7655 of 5 stars$13.98-2.4%$37.56+168.6%+26.5%$1.17B$300K0.0050News CoverageBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298News CoverageAnalyst DowngradeMNKDMannKind2.5243 of 5 stars$3.74-0.5%$10.33+176.3%-29.7%$1.14B$285.50M37.40400Negative NewsNAGENiagen Bioscience1.3017 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M158.00120LQDALiquidia Technologies3.2333 of 5 stars$12.46-4.9%$26.89+115.8%+0.1%$1.12B$14M0.0050PCRXPacira BioSciences3.4432 of 5 stars$23.90+1.8%$26.44+10.6%+10.2%$1.09B$700.97M10.34720Positive NewsABCLAbCellera Biologics2.2654 of 5 stars$3.43-5.0%$8.33+143.0%+41.4%$1.08B$28.83M0.00500Analyst ForecastHigh Trading VolumeWVEWAVE Life Sciences4.4425 of 5 stars$6.50-2.5%$20.50+215.4%+27.4%$1.04B$108.30M-7.74240News CoverageNVAXNovavax4.4795 of 5 stars$6.30-1.1%$17.00+169.8%-42.9%$1.03B$682.16M2.381,990NTLAIntellia Therapeutics4.7158 of 5 stars$9.38-1.9%$33.37+255.7%-52.9%$990.25M$57.88M0.00600 Related Companies and Tools Related Companies Viridian Therapeutics Alternatives BGM Group Alternatives MannKind Alternatives Niagen Bioscience Alternatives Liquidia Technologies Alternatives Pacira BioSciences Alternatives AbCellera Biologics Alternatives WAVE Life Sciences Alternatives Novavax Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
